NYSE$GMED

Globus Medical Inc · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

Globus Medical's Q3 2022 performance was marked by a 10.6% increase in worldwide net sales, driven by growth in both U.S. and international markets, with Enabling Technologies showing significant growth.

Globus Medical reported a 10.6% increase in worldwide net sales for Q3 2022, reaching $254.1 million. The company's U.S. Spine business grew by 9.0%, while International Spine sales increased by 11.1%. Enabling Technologies also saw significant growth of 19.0%. GAAP net income was $47.4 million, with a diluted EPS of $0.47 and non-GAAP diluted EPS of $0.50.

  • Worldwide net sales increased by 10.6% to $254.1 million, or 12.6% on a constant currency basis.
  • U.S. Spine business grew by 9.0%, demonstrating market share gains.
  • International Spine sales increased by 11.1%, or 24.8% on a constant currency basis, reflecting increased brand recognition.
  • Enabling Technologies grew by 19.0%, driven by robotic system demand and interest in the Excelsius3D™ imaging system.

Headline financials

Total Revenue

$254M

Previous: $230M+10.6%
EPS (adj)

$0.50

Previous: $0.50+0.0%
Adjusted EBITDA

$82.8M

Previous: $78.3M+5.7%
Capital Expenditures

-$55.7M

Previous: -$39.9M-39.8%
Free Cash Flow

-$8.28M

Previous: $7.36M-212.5%
Net Income

$47.4M

Previous: $47.2M+0.5%
Operating Income

$59.7M

Previous: $53.3M+12.0%
Gross Profit

$189M

Previous: $171M+10.2%
Cash & Equivalents

$134M

Previous: $362M-62.9%
Total Assets

$1.98B

Previous: $1.91B+3.5%
Stock-Based Comp

$8.31M

Previous: $7.45M+11.6%

Revenue & EPS history

Globus Medical · Revenue · Quarterly

$254M

Q3 2022+10.6%vs Q3 2021
Beat estimate in 13 of 15 quarters(87%)
ActualEstimate

Revenue by segment

Globus Medical · $254M total across 2 segments · Q3 2022

  • Musculoskeletal Solutions
    $230M+9.8%
  • Enabling Technologies
    $24.1M+19.0%

Forward guidance

The Company reaffirmed its full year 2022 guidance of $1.025 billion in net sales and decreased full year 2022 guidance for non-GAAP diluted earnings per share to $2.03 from $2.10 to account for the impact of unfavorable currency fluctuations and a higher effective tax rate.

Tailwinds

  • Reaffirmed full year 2022 net sales guidance of $1.025 billion.

Headwinds

  • Decreased full year 2022 non-GAAP diluted earnings per share guidance to $2.03 from $2.10.
  • Guidance revision due to unfavorable currency fluctuations.
  • Guidance revision due to a higher effective tax rate.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

+0.8%

Avg return

Earnings day

+0.7%

Avg return

5 days after

+0.9%

Avg return

30 days after

57%

34 / 60 earnings

Positive

+36.0%

Q3 2025

Best reaction

-23.0%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-5.1%-14.6%-10.4%
Q4 2025+4.6%+2.1%-8.8%
Q3 2025+36.0%+37.3%+47.6%
Q1 2025-23.0%-19.7%-17.3%
Q4 2024-4.6%-4.9%-12.5%
Q3 2024+10.7%+8.2%+11.2%
Q2 2024+4.0%+8.0%+4.4%
Q1 2024+22.8%+28.7%+31.6%
Q4 2023+2.2%+4.6%-3.1%
Q3 2023-1.4%-5.1%-2.5%
Q2 2023-5.0%-4.8%-9.1%
Q1 2023+2.9%-0.3%-1.8%
Q4 2022-1.2%-21.9%-29.2%
Q3 2022-4.2%+9.4%+11.5%
Q2 2022+5.4%+6.9%-2.4%
Q1 2022+0.1%+5.2%+0.1%
Q4 2021-3.1%-3.7%+1.3%
Q3 2021+0.2%-4.3%-19.4%
Q2 2021-3.3%-3.0%+1.3%
Q1 2021+3.1%+3.0%-0.9%
Q4 2020-5.7%-5.2%-10.2%
Q3 2020+2.4%+3.5%+16.9%
Q2 2020+18.5%+13.4%+13.3%
Q1 2020+8.1%+0.6%+21.4%
Q4 2019-2.1%-9.7%-29.0%
Q3 2019+3.6%+4.2%+8.2%
Q2 2019+9.9%+6.1%+12.0%
Q1 2019-1.9%-2.0%-11.0%
Q4 2018+0.2%-2.2%-0.3%
Q3 2018-8.7%-9.9%-19.4%
Q2 2018+4.7%+1.7%+3.5%
Q1 2018-3.4%+0.7%+12.6%
Q4 2017+0.5%-1.8%+2.2%
Q3 2017+9.8%+19.7%+24.3%
Q2 2017-5.2%-3.7%-1.7%
Q1 2017+4.9%+1.0%+4.7%
Q4 2016-3.1%-2.1%+2.5%
Q3 2016-5.6%-4.9%+7.1%
Q2 2016-14.3%-11.7%-13.1%
Q1 2016-9.4%
Q4 2015+4.2%
Q3 2015+12.3%
Q2 2015+2.5%
Q1 2015+4.8%
Q4 2014-0.9%
Q3 2014+7.0%
Q2 2014-16.8%
Q1 2014+6.1%
Q4 2013+1.4%
Q3 2013+7.1%
Q2 2013+2.3%
Q1 2013+7.9%
Q1 2011+0.4%
Q4 2010+0.4%
Q4 2012+5.8%
Q3 2011-20.7%
Q3 2012-16.2%
Q4 2011-0.7%
Q2 2011-0.7%
Q2 2012+0.0%
Q1 2012

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro